HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Tanveer A. Khan Pierre Voisine Frank W. Sellke Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khan, T. A. Articles by Sellke, F. W. Search for Related Content PubMed PubMed Citation Articles by Khan, T. A. Articles by Sellke, F. W. Related Collections Myocardial protection

J Thorac Cardiovasc Surg 2004;128:602-608
© 2004 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest

^a Department of Surgery, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Mass, USA
^b Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass, USA

Received for publication October 21, 2003; revisions received February 9, 2004; accepted for publication March 17, 2004.

^* Address for reprints: Frank W. Sellke, MD, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, 110 Francis St, LMOB 2A, Boston, MA 02215, USA
fsellke{at}caregroup.harvard.edu

BACKGROUND: Surgical coronary revascularization with cardiopulmonary bypass and cardioplegia has been associated with reperfusion injury. The serine protease inhibitor aprotinin has been suggested to reduce reperfusion injury, yet a clinically relevant study examining regional ischemia under conditions of cardiopulmonary bypass and cardioplegia has not been performed.

METHODS: Pigs were subjected to 30 minutes of regional myocardial ischemia by distal left anterior descending coronary artery occlusion, followed by 60 minutes of cardiopulmonary bypass with 45 minutes of cardioplegic arrest and 90 minutes of post–cardiopulmonary bypass reperfusion. The treatment group (n = 6) was administered aprotinin systemically (40,000 kallikrein-inhibiting units [KIU]/kg intravenous loading dose, 40,000 KIU/kg pump prime, and 10,000 KIU · kg^–1 · h^–1 intravenous continuous infusion). Control animals (n = 6) received crystalloid solution. Global and regional myocardial functions were analyzed by the left ventricular+dP/dt and the percentage segment shortening, respectively. Left ventricular infarct size was measured by tetrazolium staining. Tissue myeloperoxidase activity was measured. Myocardial sections were immunohistochemically stained for nitrotyrosine. Coronary microvessel function was studied by videomicroscopy.

RESULTS: Myocardial infarct size was decreased with aprotinin treatment (27.0% ± 3.5% vs 45.3% ± 3.0%, aprotinin vs control; P < .05). Myocardium from the ischemic territory showed diminished nitrotyrosine staining in aprotinin-treated animals versus controls, and this was significant by grade (1.3 ± 0.2 vs 3.2 ± 0.2, aprotinin vs control; P < .01). In the aprotinin group, coronary microvessel relaxation improved most in response to the endothelium-dependent agonist adenosine diphosphate (44.7% ± 3.2% vs 19.7% ± 1.7%, aprotinin vs control; P < .01). No significant improvements in myocardial function were observed with aprotinin treatment.

CONCLUSIONS: Aprotinin reduces reperfusion injury after regional ischemia and cardioplegic arrest. Protease inhibition may represent a molecular strategy to prevent postoperative myocardial injury after surgical revascularization with cardiopulmonary bypass.

This article has been cited by other articles:

				X. Wang, Z. Zheng, H. Ao, S. Zhang, Y. Wang, H. Zhang, L. Li, and S. Hu A comparison before and after aprotinin was suspended in cardiac surgery: Different results in the real world from a single cardiac center in China J. Thorac. Cardiovasc. Surg., October 1, 2009; 138(4): 897 - 903. [Abstract] [Full Text] [PDF]

				M. D. McEvoy, A.-G. Taylor, J. A. Zavadzkas, I. M. Mains, R. L. Ford, R. E. Stroud, L. B. Jeffords, C. U. Beck, S. T. Reeves, and F. G. Spinale Aprotinin Exerts Differential and Dose-Dependent Effects on Myocardial Contractility, Oxidative Stress, and Cytokine Release After Ischemia-Reperfusion Ann. Thorac. Surg., August 1, 2008; 86(2): 568 - 575. [Abstract] [Full Text] [PDF]

				M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]

				M. Buerke, D. Pruefer, D. Sankat, J. M. Carter, U. Buerke, M. Russ, A. Schlitt, I. Friedrich, J. Borgermann, C. F. Vahl, et al. Effects of Aprotinin on Gene Expression and Protein Synthesis After Ischemia and Reperfusion in Rats Circulation, September 11, 2007; 116(11_suppl): I-121 - I-126. [Abstract] [Full Text] [PDF]

				G. Veres, T. Radovits, H. Schultz, L.-n. Lin, J. Hutter, E. Weigang, Z. Szabolcs, and G. Szabo Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass Eur. J. Cardiothorac. Surg., August 1, 2007; 32(2): 340 - 345. [Abstract] [Full Text] [PDF]

				R. Poston and O. Toshinaga Reply Ann. Thorac. Surg., November 1, 2006; 82(5): 1951 - 1952. [Full Text] [PDF]

				A. Sedrakyan, A. Wu, G. Sedrakyan, M. Diener-West, M. Tranquilli, and J. Elefteriades Aprotinin use in thoracic aortic surgery: Safety and outcomes J. Thorac. Cardiovasc. Surg., October 1, 2006; 132(4): 909 - 917. [Abstract] [Full Text] [PDF]

				M. Boodhwani, J. Feng, S. Mieno, B. Ramlawi, N. Sodha, R. Clements, and F. W. Sellke Effects of purified poloxamer 407 gel on vascular occlusion and the coronary endothelium. Eur. J. Cardiothorac. Surg., May 1, 2006; 29(5): 736 - 741. [Abstract] [Full Text] [PDF]

				T. A. Khan, C. Bianchi, E. Araujo, P. Voisine, S.-H. Xu, J. Feng, J. Li, and F. W. Sellke Aprotinin Preserves Cellular Junctions and Reduces Myocardial Edema After Regional Ischemia and Cardioplegic Arrest Circulation, August 30, 2005; 112(9_suppl): I-196 - I-201. [Abstract] [Full Text] [PDF]

				M. M. Kittleson, K. M. Minhas, R. A. Irizarry, S. Q. Ye, G. Edness, E. Breton, J. V. Conte, G. Tomaselli, J. G. N. Garcia, and J. M. Hare Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure Physiol Genomics, May 11, 2005; 21(3): 299 - 307. [Abstract] [Full Text] [PDF]